Back to Search Start Over

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

Authors :
UCL - MD/CHIR - Département de chirurgie
UCL - (SLuc) Service de chirurgie et transplantation abdominale
UCL - (SLuc) Centre du cancer
Charpentier, Bernard
Rostaing, Lionel
Berthoux, François
Lang, Philippe
Civati, Giovanni
Touraine, Jean-Louis
Squifflet, Jean-Paul
Vialtel, Paul
Abramowicz, Daniel
Mourad, Georges
Wolf, Philippe
Cassuto, Elisabeth
Moulin, Bruno
Rifle, Gerard
Pruna, André
Merville, Pierre
Mignon, Françoise
Legendre, Christophe
Le Pogamp, Patrick
Lebranchu, Yvon
Toupange, Olivier
Hurault de Ligny, Bruno
Touchard, Guy
Olmer, Michel
Purgus, Raj
Pouteil-Noble, Claire
Glotz, Denis
Bourbigot, Bernard
Leski, Michel
Wauters, Jean-Pierre
Kessler, Michèle
UCL - MD/CHIR - Département de chirurgie
UCL - (SLuc) Service de chirurgie et transplantation abdominale
UCL - (SLuc) Centre du cancer
Charpentier, Bernard
Rostaing, Lionel
Berthoux, François
Lang, Philippe
Civati, Giovanni
Touraine, Jean-Louis
Squifflet, Jean-Paul
Vialtel, Paul
Abramowicz, Daniel
Mourad, Georges
Wolf, Philippe
Cassuto, Elisabeth
Moulin, Bruno
Rifle, Gerard
Pruna, André
Merville, Pierre
Mignon, Françoise
Legendre, Christophe
Le Pogamp, Patrick
Lebranchu, Yvon
Toupange, Olivier
Hurault de Ligny, Bruno
Touchard, Guy
Olmer, Michel
Purgus, Raj
Pouteil-Noble, Claire
Glotz, Denis
Bourbigot, Bernard
Leski, Michel
Wauters, Jean-Pierre
Kessler, Michèle
Source :
Transplantation, Vol. 75, no. 6, p. 844-851 (2003)
Publication Year :
2003

Abstract

Background. Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients. Methods. In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n= 186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine, and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy. Results. Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05). Conclusions. Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.

Details

Database :
OAIster
Journal :
Transplantation, Vol. 75, no. 6, p. 844-851 (2003)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1130565577
Document Type :
Electronic Resource